Navigation Links
Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
Date:9/14/2010

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) was presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"Patients with CDI often have persistent infections or develop new infections during the course of CDI treatment and are often administered concomitant antibiotics. Although clinically necessary the use of concomitant antibiotics has a deleterious effect on outcomes of cure, recurrence and global cure. Compared to vancomycin therapy, fidaxomicin blunts these negative effects by significantly lowering recurrences and increasing global cure of patients," said Pedro Lichtinger, Optimer's President and Chief Executive Officer.  "The additional data presented suggest fidaxomicin has the potential to become the product of choice for CDI, if approved."

Kathleen M. Mullane, D.O., Pharm. D., an investigator from the University of Chicago, Department of Medicine, Section of Infectious Diseases, in Illinois, presented combined data from Optimer's two Phase 3 trials indicating that the use of concomitant antibiotics is a significant risk factor for a negative CDI treatment outcome.  Many patients with CDI have persistent infections or develop new infections during the course of CDI treatment making concomitant antibiotics clinically necessary and common.  Overall, 34% of subjects received antibiotics in addition to fidaxomicin a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
2. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
4. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
5. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
6. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
7. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
8. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
9. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Stemedica Announces Completion of Clinical Stem Cell Master Bank
11. DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... The New Jersey chapter of the ... Processing Associates (BDPA), is hosting its 10th annual Families ... all-day event will encourage students and their parents to ... outs from many of the industries’ finest teachers. Held ... Jersey Institute of Technology, the event will include workshops, ...
(Date:5/23/2013)... 2013  Verenium Corporation (Nasdaq: VRNM ), ... and commercialization of high-performance enzymes, today announced that ... present at two upcoming conferences. (Logo: ... the Second Annual Marcum LLP Microcap Conference on Thursday, ... New York City.  The presentation is scheduled to begin ...
(Date:5/23/2013)... South Korea , May 23, 2013 /PRNewswire/ ... with SillaJen, Inc., a private biotherapeutics and contract ... targeted biological products for cancer, announced today a ... in patients treated with the oncolytic and immunotherapeutic ... This research was published in the May ...
(Date:5/23/2013)... 23, 2013 African Ancestry ... for people of African descent, today announced new ... For people of all races, myDNAmix determines various ... distinct populations: Indigenous Americas (Native American), East Asia, ... , Originally launched in late 2011, ...
Breaking Biology Technology:Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3
... Inc. announced today Winchester Hospital ... of APIs suite of labor resource management solutions ... include Payrollmation time and attendance, ActiveStaffer staff scheduling, ... , ,The hospital is adopting the applications in ...
... MILWAUKEE - Merge eFilm , a global ... the release of eFilm Workstation 1.9 and ... PACS for 10 imaging centers. , ,eFilm Workstation ... the ability to view and manipulate digital diagnostic ...
... long-standing riddle of whether the Earth's ice ages occurred simultaneously ... the glacial deposits found in the high desert east of ... effects of cosmic rays on minerals found in boulders carried ... of scientists from the University of Wisconsin-Madison has demonstrated that ...
Cached Biology Technology:Glacial records depict ice age climate in synch worldwide 2Glacial records depict ice age climate in synch worldwide 3
(Date:5/22/2013)... feared Legionella pneumophila bacteria is responsible for ... In order to infect us, this pathogen has developed ... go unnoticed in our cells, thus avoiding these acting ... Basque biosciences research centre, CIC bioGUNE, in which teams ... USA and the National Supercomputation Centre in Barcelona (BSC) ...
(Date:5/22/2013)... Early screening for prostate cancer could become as ... women, thanks to UC Irvine research published today in ... , After more than a decade of work, UC ... clinically usable markers for prostate cancer in urine, meaning ... greater accuracy and at dramatically lower cost. The same ...
(Date:5/22/2013)... May 22, 2013. Plastic additives known as phthalates ... everywhere: They turn up in flooring, plastic cups, ... the Centers for Disease Control and Preventionthe bodies ... have come under increasing scrutiny. A growing collection ... can leech from packaging and mix with food) ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2
... Four new studies addressing basic questions about how ... by the National Science Foundation,s (NSF) Division of ... just over $1.3 million, NSF,s awards for these ... and about fundamental biological responses to environmental changes, ...
... States and United Kingdom are signing a memorandum ... atmospheric science and technology. The agreement will enable ... developing joint educational and training programs. The ... the U.S. National Center for Atmospheric Research (NCAR) ...
... devote more resources to research into the effects ... to a paper published today in the journal ... Research Flagship. ,"Marine ecosystems are undoubtedly under-resourced, overlooked ... impacts on marine life is a mere drop ...
Cached Biology News:National Science Foundation funds research addressing enduring questions of life 2National Science Foundation funds research addressing enduring questions of life 3National Science Foundation funds research addressing enduring questions of life 4US and UK research centers launch major collaboration on atmospheric research, technology 2Ocean life under threat from climate change 2
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
... This DuoSet ELISA Development kit contains the ... sandwich ELISAs to measure natural and recombinant ... supernates and serum. Each kit contains sufficient ... 96-well plates, provided that the following conditions ...
HES-1 [Hairy 1], Available Summer 2003...
E1A (adenovirus early region 1)...
Biology Products: